valu usd unless otherwis note
two new survey told us
impact bullish skyrizi long term
view ran two separ survey gaug physician view around
pso treatment pattern amidst implic skyrizi/
humira bottom line expect drug take near-term hit
revenu forecast reflect expect impact
transitori bullish long-term skyrizi outlook said differ
look see favor risk/reward
conduct two separ dermatolog survey better assess
psoriasi pso treatment trend amidst on-going
pandem pso import market account
total revenu humira skyrizi lower
full-year revenu forecast humira skyrizi
link want delv deeper market dynam
given low visibl first survey take broader look
overal treatment landscap second survey look
close skyrizi see exhibit full result import us
appear unlik last impact skyrizi growth
outlook consist kol check anyth believ
skyrizi could benefit gradual shift away anti-tnf agent
continu monitor weekli gaug earli impact
substant updat like come earn
near term survey suggest modest downsid humira
skyrizi consist expect roughli two-third
physician expect total pso patient treat new patient start
declin next three month rest expect chang
reduc physician access like play role given preval
offic closur non-emerg set humira anti-tnf
agent gener physician also express concern around safeti
 immunosuppress context point
could see near-tim pressur pro-forma ep led
aesthet busi detail link think
temporari pull-back relat volatil could
repres opportun given strength core product franchis
said think share increasingli interest
longer term physician still expect increas usag skyrizi
meaning per second survey physician current prescrib
skyrizi patient moderate-to-sever psoriasi
prescrib least patient one year
physician expect prescrib skyrizi pso patient
number move even higher three year potenti
survey bia asid illustr high degre physician confid
skyrizi help sustain sale momentum well beyond
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
base case see price target impli price-to-earnings
pro-forma ep
assum may deal close allergan
specif addit accret built estim
expect continu annual busi develop
strong uptak key growth product skyrizi
assum slowdown
econom downturn
upsid case scenario see price target impli
price-to-earnings pro-forma ep
invest thesi base medium term
growth concern stem us humira loss
exclus loe replac gap lower-growth
asset announc allergan acquisit expect
close legaci portfolio struggl
strateg fit allergan deal serv
help combin compani navig loe provid
suffici cash flow support continu strateg deploy
capit thesi base follow key point
support sector perform rate
allergan acquisit help compani navig
humira cliff see opportun divest lower
growth asset addit provid attract add
product dilut growth profil combin
compani said see potenti futur strateg
action could creat valu ie divest non-cor
franchis bolster cash flow near-term
strength immunolog clear
core compet compani built power hous
humira provid benefit launch skyrizi
rinvoq add two solid long-term growth driver
expect near-term impact particularli
aesthet busi see busi solidli
posit long-term also see ad option
around potenti ipo sale road meantim
add cash flow support busi dividend
bigger opportun view pursu deal inflect
faster uptak key growth product skyrizi
assum deal close allergan addit
accret built estim
lower humira eros follow us loss exclus
quicker clear relat pandem
potenti catalyst close allergan acquisit may
sever data read focu rinvoq ph data
atop derm skyrizi motiv data
cd induct bi voltaire-x interchang studi
read-out biosimilar humira head-to-head calquence/
imbruvica data r/r cll
risk thesi delay close allergan deal
competit risk particularli around hem-onc franchis
botox slower uptak key grower greater
expect impact
downsid case scenario see price target
impli price-to-earnings downsid pro-forma ep
sluggish uptak key growth product skyrizi
assum prolong deal closur allergan and/or
stringent ftc divestitur requir expect
aggress humira eros follow us loss
exclus expect
greater impact expect
survey result survey look impact
psoriasi treatment landscap
survey dermatologist treat patient moderate-to-sever psoriasi
survey result exhibit particular interest us feedback around
humira skyrizi play meaning role treatment paradigm
overal anticip near-term chang pso treatment larg increment
gener view total patient treat declin pandem
exhibit result first survey dermatologist treat moderate-to-sever psoriasi patient
major physician expect total pso patient treat new patient start declin
next three month due pandem make sens us
consid larg number non-emerg medic offic close
certain logist difficulti start patient new biolog therapi remot
survey questionsresponsescommentsavgadalimumab number rang pso patient per month screen physician treat less patient per pandem began us break-out treatment moderate-to-sever psoriasi patient expect humira clear market leader psoriasi market share among survey physician pre-pandem skyrizi came market mani patient moderate-to-sever psoriasi treat per month patient per long pandem on-going us expect break-out treatment moderate-to-sever psoriasi patient humira could potenti lose market share pandem increas skyrizi usag could help off-set said number taken caution given small sampl pandem end us estim break-out treatment moderate-to-sever psoriasi patient go-forward basi physician expect skyrizi usag continu grow pandem end consist feedback second survey exhibit result first survey dermatologist treat moderate-to-sever psoriasi patient cont
shown exhibit physician concern around safeti amidst highest
anti-tnf class drug includ humira surpris given
immunosuppress natur drug
survey questionsresponsescom respect overal patient treat next month level chang expect rel normal use prior pandem major physician expect number overal patient treat declin next three month come surpris given magnitud anticip relat disrupt respect new patient start next month level chang expect rel normal use prior pandem new patient start also expect declin significantli approxim two-third physician expect declin next three month could outsiz albeit temporari impact skyrizi remain earli launch curv exhibit result first survey dermatologist treat moderate-to-sever psoriasi patient cont
tnf inhibitorsnonon anti tnf snonon anti-tnf alphano target cyclosporin methotrex mycophenolatenonetnf alpha inhibitorshumiranonetnf inhibitorshumiranonetnf inhibitor specif stelaranonetnf humira/enbrelinfliximab longer act biologicsnoney nanonewith respect immun target biologics/ag treat moderate-to-sever psoriasi agent prescrib less often due potenti safeti issu relat risk viral infect abbvi inc
survey closer look near long-term outlook skyrizi
second survey dermatologist take closer look skyrizi result
exhibit poll physician near-term expect usag well
long-term expect one three year feedback mix
expect skyrizi long-term growth outlook appear intact
exhibit result second survey dermatologist treat moderate-to-sever psoriasi patient
also ask physician direct impact usag skyrizi
result exhibit interest feedback two
survey fewer patient visit clearli factor concern around safeti less
survey questionsresponsescommentsavg percentag total moderate-to-sever psoriasi patient expect treat skyrizi one year three year respect physician expect continu strong growth number patient treat skyrizi next year expect skyrizi share one year skyrizi share three year number second survey rang pso patient per month screen physician treat less patient per factor account includ expect usag skyrizi total number prescript chang next three month april june compar preced three month period januari march mix view expect skyrizi usag roughli equal number physician anticip increas versu declin total prescript suggest flat quarter-over-quart revenu larg consist percentag total moderate-to-sever psoriasi patient current treat skyrizi percentag patient treat skyrizi usag came slightli higher first survey meaning mani patient moderate-to-sever psoriasi treat per month patient per exhibit result second survey dermatologist treat moderate-to-sever psoriasi patient cont
fewer patient seenno think immunosuppress skyrizi significantli increas risk covid infect ye decreas believ treatment less immunosuppress therefor safer downstream blockad like safer anti tnfye due low pt volum closur offic use skyrizino relevanty take patient biologicsi think switch patient given safeti profileno continu patient well control toler well ye like decreas due low patient volumesi think il safer attempt use moreno safest ye decreas use inhibitor due concern increas suscept covid infect medicationsincreas switch patient tnfano evid skyrizi pose increas risk contract would prefer avoid new start biolog pandemicit decreas data determin whether biolog like skyrizi safe use time long run seem product less immunosuppress biolog rx might actual go endy short term sinc patient come inless offic time consid safer biolog option realli biolog dont want start nowy decreaseless pandem overnot start new patient biologicsy less immunosuppressingmay decreas number new prescript patient hesitanty target therapi switch tnfi skyrizi reduc immunosuppressionnoposs increas uriy fewer patient therefor fewer need patient nervou biologicsnous decreas less patient volum less interest patient start system immun suppress medy im choos med immunosuppress minim immunosuppress difficult get patient iny lower infect rate biologicsno visit convert video visit yesy recommend number appoint reduc chang patient needsy see fewer patient ye switch shorter act biolog case infectionno chang start use yety mani patient seen offic less opportun start ye cancel clinic next week wont initi new script thenno impact ye patient hesit use immunosuppressantdo expect directli impact usag skyrizi pleas explain exhibit
 incom guid appr op growth product profit guid guid guid salesoper incom guid sale expens guid billionnet foreign exchang incom expens interest expens incom tax tax guid adjust tax rate earn ep guid share share guid flatdividend per increas announc yield price dividend yield assum annual increasesebitda guid guid guid salesoper guid sale guid profit analysi guid appr op growth share per inc
price target base equal ev/ebitda price-to-earnings estim reflect
close allergan acquisit use multipl respect
reflect meaning discount histor industri averag adjust us loss
exclus humira impli return price target support sector
risk rate price target
risk rate price target includ limit tail valu risk
humira still meaning contributor combin compani acquisit risk work
close integr allergan transact largest deal histori
regulatory/polit risk broadli applic sector particularli around pricing/
global biopharmaceut compani base chicago il spun
abbott becam independ publicly-trad compani compani
track record acquisit pharmacycl stemcentrx
announc acquisit allergan expect close upon
close allergan transact combin compani focus immunolog
hematolog oncolog medic aesthet neurosci franchis
